Goldman Sachs analyst Terence Flynn upgraded CytomX Therapeutics (NASDAQ: CTMX) from Neutral to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE